BI
ALPN

BVF Inc’s Alpine Immune Sciences Inc ALPN Stock Holding History

BVF Inc’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-858,339
Closed -$6.63M – 75
2023
Q1 		$6.63M Sell
858,339
-277,601
-24% -$2.21M 0.24% 55
2022
Q4 		$8.35M Hold
1,135,940
– – 0.35% 50
2022
Q3 		$8.18M Sell
1,135,940
-139,300
-11% -$1.15M 0.34% 54
2022
Q2 		$10.9M Sell
1,275,240
-314,255
-20% -$2.71M 0.52% 48
2022
Q1 		$14.3M Hold
1,589,495
– – 0.57% 48
2021
Q4 		$22M Hold
1,589,495
– – 0.8% 36
2021
Q3 		$17M Buy
+1,589,495
New +$14.6M 0.66% 41
2020
Q2 		– Sell
-1,137,764
Closed -$3.28M – 63
2020
Q1 		$3.28M Hold
1,137,764
– – 0.31% 47
2019
Q4 		$4.37M Hold
1,137,764
– – 0.33% 42
2019
Q3 		$4.46M Sell
1,137,764
-13,953
-1% -$59.9K 0.47% 47
2019
Q2 		$4.85M Sell
1,151,717
-50,000
-4% -$289K 0.53% 43
2019
Q1 		$8.24M Buy
1,201,717
+558,658
+87% +$3.48M 0.92% 36
2018
Q4 		$2.37M Hold
643,059
– – 0.31% 46
2018
Q3 		$4.07M Hold
643,059
– – 0.36% 48
2018
Q2 		$4.87M Sell
643,059
-32,700
-5% -$269K 0.48% 42
2018
Q1 		$5.41M Hold
675,759
– – 0.55% 35
2017
Q4 		$7.57M Hold
675,759
– – 0.91% 27
2017
Q3 		$7.84M Buy
675,759
+14,557
+2% +$136K 1% 28
2017
Q2 		$6.37M Buy
661,202
+195,083
+42% +$1.87M 0.99% 24
2017
Q1 		$5.44M Hold
466,119
– – 0.93% 24
2016
Q4 		$4.18M Buy
466,119
+38,701
+9% +$771K 0.84% 23
2016
Q3 		$13.9M Sell
427,418
-54,193
-11% -$1.32M 2.62% 14
2016
Q2 		$8.86M Buy
481,611
+94,925
+25% +$1.68M 1.89% 16
2016
Q1 		$6.45M Buy
386,686
+87,933
+29% +$1.76M 1.6% 20
2015
Q4 		$9.25M Buy
+298,753
New +$10.2M 1.58% 19

Other funds holding ALPN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BVF Inc's ALPN Position: Q2 2023 in Review

BVF Inc sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2023, closing a stake of 858,339 shares — an estimated $6.63M sold.

BVF Inc first reported a position in ALPN in Q4 2015 and held it in 25 quarters. The position peaked at $22M in Q4 2021. 76 funds tracked by Wall St. Rank hold ALPN as of Q2 2023.

  • BVF Inc reported no remaining Alpine Immune Sciences Inc position as of Q2 2023 after selling out during the quarter.
  • BVF Inc sold 858,339 Alpine Immune Sciences Inc shares in Q2 2023, an estimated $6.63M.
  • BVF Inc first reported a position in Alpine Immune Sciences Inc in Q4 2015 and held it in 25 quarters.
  • BVF Inc's Alpine Immune Sciences Inc position peaked at $22M in Q4 2021.
  • 76 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2023.

Based on BVF Inc's 13F filing for Q2 2023, filed 14 Aug 2023.